Targeting the residual leukemia cells after chemotherapy Journal Article

  


Authors: Vu, L. P.; Kharas, M. G.
Article Title: Targeting the residual leukemia cells after chemotherapy
Abstract: One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence. One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence. © 2018 Elsevier Inc.
Journal Title: Cancer Cell
Volume: 34
Issue: 3
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2018-09-10
Start Page: 353
End Page: 355
Language: English
DOI: 10.1016/j.ccell.2018.08.012
PROVIDER: scopus
PUBMED: 30205040
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052733697&doi=10.1016%2fj.ccell.2018.08.012&partnerID=40&md5=a3a49951cfb31d3ead1630794c866b2d
Notes: Short Survey -- Export Date: 1 October 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ly P Vu
    34 Vu
  2. Michael Kharas
    96 Kharas
Related MSK Work